A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs

Jörg Tenhündfeld Small Animal Clinic, University of Veterinary Medicine, D-30173 Hanover, Germany.

Search for other papers by Jörg Tenhündfeld in
Current site
Google Scholar
PubMed
Close
 DVM
,
Patrick Wefstaedt Small Animal Clinic, University of Veterinary Medicine, D-30173 Hanover, Germany.

Search for other papers by Patrick Wefstaedt in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Ingo J. A. Nolte Small Animal Clinic, University of Veterinary Medicine, D-30173 Hanover, Germany.

Search for other papers by Ingo J. A. Nolte in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To investigate the effects of benazepril and heparin on renal function and blood pressure in dogs with chronic kidney disease.

Design—Randomized controlled clinical trial.

Animals—26 dogs with chronic kidney disease.

Procedures—Dogs were randomly assigned to receive benazepril hydrochloride (0.5 mg/kg [0.23 mg/lb], PO, q 24 h; n = 10), benazepril and heparin (150 U/kg [68 U/lb], SC, q 8 h, for the first 6 days; 10), or a placebo (6) and were followed up for 180 days.

Results—Health status score at the end of the study (ie, day 180) was significantly higher for dogs in the 2 treatment groups than for dogs in the placebo group. In addition, glomerular filtration rate was significantly increased and the urine protein-to-creatinine ratio was significantly decreased, compared with baseline rates, at the end of the study for dogs in both treatment groups but not for dogs in the placebo group. Systolic and diastolic blood pressures were significantly decreased on day 6 for dogs in both treatment groups.

Conclusions and Clinical Relevance—Results suggested that administration of benazepril had beneficial effects in dogs with chronic kidney disease but that short-term administration of heparin in conjunction with benazepril did not appear to provide any additional benefit.

Abstract

Objective—To investigate the effects of benazepril and heparin on renal function and blood pressure in dogs with chronic kidney disease.

Design—Randomized controlled clinical trial.

Animals—26 dogs with chronic kidney disease.

Procedures—Dogs were randomly assigned to receive benazepril hydrochloride (0.5 mg/kg [0.23 mg/lb], PO, q 24 h; n = 10), benazepril and heparin (150 U/kg [68 U/lb], SC, q 8 h, for the first 6 days; 10), or a placebo (6) and were followed up for 180 days.

Results—Health status score at the end of the study (ie, day 180) was significantly higher for dogs in the 2 treatment groups than for dogs in the placebo group. In addition, glomerular filtration rate was significantly increased and the urine protein-to-creatinine ratio was significantly decreased, compared with baseline rates, at the end of the study for dogs in both treatment groups but not for dogs in the placebo group. Systolic and diastolic blood pressures were significantly decreased on day 6 for dogs in both treatment groups.

Conclusions and Clinical Relevance—Results suggested that administration of benazepril had beneficial effects in dogs with chronic kidney disease but that short-term administration of heparin in conjunction with benazepril did not appear to provide any additional benefit.

  • 1.

    Cowgill LD, Kallet AJ. Systemic hypertension. In: Kirk RW, ed. Current veterinary therapy IX: small animal practice. London: Saunders, 360364.

    • Search Google Scholar
    • Export Citation
  • 2.

    Jacob F, Polzin DJ, Osborne CA, et al. Systemic hypertension in dogs with spontaneous chronic kidney disease: prevalence, target-organ damage and survival. J Vet Intern Med 1999;13:253.

    • Search Google Scholar
    • Export Citation
  • 3.

    Ross LA. Hypertension and chronic renal failure. Semin Vet Med Surg (Small Anim) 1992;7:221226.

  • 4.

    Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Intern Med 2000;14:526533.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Brown SA, Finco DR, Brown CA, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res 2003;64:321327.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Lefebvre HP, Toutain PL. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Ther 2004;27:265281.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Brown SA, Walton CL, Crawford P. Long-term effects of antihypertensive regimens on renal haemodynamics and proteinuria. Kidney Int 1993;43:12101218.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Gaber L, Walton C, Brown S, et al. Effect of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994;46:161169.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Grauer GF. Canine glomerulonephritis: new thoughts on proteinuria and treatment. Anim Pract 2005;46:469478.

  • 10.

    Lefebvre HP, Brown SA, Chetboul JN, et al. Angiotensin-converting enzyme inhibitors in veterinary medicine. Curr Pharm Des 2007;13:13471361.

  • 11.

    Waldmeier F, Schmid K. Disposition of [14C]-benazepril hypochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion. Arzneimittelforschung 1989;39:6267.

    • Search Google Scholar
    • Export Citation
  • 12.

    Sica DA. Kinetics of angiotensin-converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992;20:1320.

  • 13.

    King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res 1995;56:16201628.

    • Search Google Scholar
    • Export Citation
  • 14.

    Toutain PL, Lefebvre HP, Laroute V. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs. J Pharmacol Exp Ther 2000;292:10941103.

    • Search Google Scholar
    • Export Citation
  • 15.

    Mischke R. Veränderungen der Hämostase bei Hunden mit chronischer Niereninsuffizienz. Berl Munch Tierarztl Wochenschr 1997;110:445450.

    • Search Google Scholar
    • Export Citation
  • 16.

    Mischke RH, Schüttert C, Grebe SI. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001;62:18871891.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Hirsh J, Warkentin TE, Shaugnessey SS, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficiency, and safety. Chest 2001;119:6494.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Brown SA, Finco DR, Boudinot FD, et al. Evaluation of a single injection method, using iohexol, for estimating glomerular filtration rate in cats and dogs. Am J Vet Res 1996;57:105110.

    • Search Google Scholar
    • Export Citation
  • 19.

    Meyer-Lindenberg A, Westhoff A, Wohlsein P, et al. Measurement of glomerular filtration rate (GFR) after administration of iodine contrast medium with the Renalyzer PRX90 in healthy cats and cats with kidney diseases [in German]. Berl Munch Tierarztl Wochenschr 1998;111:344351.

    • Search Google Scholar
    • Export Citation
  • 20.

    Mischke R, Nolte I. Optimization of prothrombin time measurements in canine plasma. Am J Vet Res 1997;58:236241.

  • 21.

    Leopold-Temmler B, Nolte I. Verlaufsuntersuchung von nierenkranken Hunden mit der Sodium Dodecyl Sulfat-Polyacrylamid-Gradientengel Urinelectrophorese. Kleintierprax 1995;40:103113.

    • Search Google Scholar
    • Export Citation
  • 22.

    Janthur M, Wirth W. Sonographische Erscheinungsbilder der Hundeniere im Vergleich zur pathologisch-histologischen Morphologie. Berl Munch Tierarztl Wochenschr 1997;110:102110.

    • Search Google Scholar
    • Export Citation
  • 23.

    Barr FJ, Holt PE, Gibbs C. Ultrasonographic measurement of normal renal parameters. J Small Anim Pract 1990;31:180184.

  • 24.

    Lombard CW. Normal values of the canine M-mode echocardiogram. Am J Vet Res 1984;45:20152018.

  • 25.

    Tenhündfeld J, Nolte I. Standardized measurement of the glomerular filtration rate (GFR) through controlled infusion therapy in healthy dogs. Tierarztl Umsch 2007;62:553560.

    • Search Google Scholar
    • Export Citation
  • 26.

    International Renal Interest Society (IRIS) Web site. Iris 2006 Staging of CKD. Available at: www.iris-kidney.com/pdf/IRIS%202006%20Staging%20of%20CKD.pdf. Accessed Jul 20, 2008.

    • Search Google Scholar
    • Export Citation
  • 27.

    Cowgill LD, James KM, Levy JK, et al. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc 1998;212:521528.

    • Search Google Scholar
    • Export Citation
  • 28.

    King LG, Giger U, Diserens D, et al. Anemia of chronic renal failure in dogs. J Vet Intern Med 1992;6:264270.

  • 29.

    Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000;35:179188.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Purkerson ML, Tollefsen DM, Klahr S. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 1988;81:6974.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Nagode LA, Chew DJ, Podell M. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent or suppress toxic hyperparathyroidism. Vet Clin North Am Small Anim Pract 1996;26:12931330.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Oikawa T, Freeman M, Lo W, et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997;51:164172.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Volpert A, Nolte I, Käufer-Weiss I. Vertikale Sodium Dodecyl Sulfat-Polyacrylamid-Gradientengel Elektorphorese im Mikrosystem zur Differenzierung von Urinproteinen in der Diagnostik von Nierenerkrankungen beim Hund. Tierarztl Prax Suppl 1989;5:2428.

    • Search Google Scholar
    • Export Citation
  • 34.

    Minkus G, Reusch C, Hörauf A, et al. Evaluation of renal biopsies in cats and dogs—histopathology in comparison with clinical data. J Small Anim Pract 1994;35:465472.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Brown SA, Brown CA, Jacobs G, et al. Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. Am J Vet Res 2001;62:375383.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement